NIH-funded study suggests GLP-1 drugs may extend lifespan in mice
What happened
The National Institutes of Health funded research conducted at the University of California. The study found that the GLP-1 drug semaglutide extended the lifespan of older, healthy mice by tempering the effects of aging. Mice treated with the drug also showed improved muscle and cognitive function compared with a control group.
Why it matters
The findings could have significant implications for the rapidly expanding GLP-1 drug market. The research suggests that the drugs’ effects may extend beyond simply mimicking the benefits of a lower-calorie diet, pointing to fundamental anti-aging effects.
Government bodies, including the National Institutes of Health, supported foundational science research, and Cynthia Kenyon served as an emeritus professor at the institution.
Who's involved
- National Institutes of HealthProvided foundational funding for the research
- University of CaliforniaConducted the academic research on the GLP-1 drug
- Eli Lilly and CompanyIs a competitor in the GLP-1 drug market
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
National Institutes of Health
government organization in Shah Alam, Malaysia
-
University of California
university system in California, United States
Related events
- The National Institutes of Health awarded funding for research and health programs to the University of Nebraska Medical Center.
- NIH provided federal grant funding to UF for research.
- The National Institutes of Health funded research at Quillen College of Medicine.
- NIH, NSF, and CEPI provided research grants and investment to university faculty on August 4, 2026.
- A controversy regarding NIH control has emerged, involving the American Heart Association.